Liberum Capital reissued their hold rating on shares of Shire (LON:SHP) in a research note published on Wednesday. They currently have a GBX 4,000 ($55.26) price objective on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on the stock. Barclays reaffirmed an equal weight rating and issued a GBX 4,000 ($55.26) price objective on shares of Shire in a research note on Monday, October 30th. Shore Capital reaffirmed a buy rating on shares of Shire in a research note on Thursday, October 26th. Goldman Sachs Group reissued a conviction-buy rating on shares of Shire in a research report on Tuesday, October 17th. Citigroup reissued a buy rating and set a GBX 5,500 ($75.99) target price on shares of Shire in a research report on Friday, December 8th. Finally, cut their target price on shares of Shire from GBX 4,480 ($61.90) to GBX 4,050 ($55.95) and set a hold rating for the company in a research report on Tuesday, October 31st. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of GBX 5,173.53 ($71.48).
Shares of Shire (LON:SHP) opened at GBX 3,202 ($44.24) on Wednesday. Shire has a 52 week low of GBX 3,034 ($41.92) and a 52 week high of GBX 5,067 ($70.01). The stock has a market cap of $28,920.00 and a price-to-earnings ratio of 618.15.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/02/18/shire-shp-stock-rating-reaffirmed-by-liberum-capital.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.